GSH, TAD 600 (Italy)
A tripeptide of glutamate, cysteine and glycine. It is the body’s main antioxidant inside cells.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026.
TAD, Italy
600 mg IM or slow IV for ongoing therapy; about 2.5 g IV before each cisplatin dose.
200–600 mg IM or SC, 2–3× per week. IV 600–1,200 mg weekly to every 2 weeks.
No set cycle, shown over 26 weeks
The ways Glutathione is most often run, each tagged with where it comes from.
The TAD label’s approved use. Dosed by body surface area and adjusted for age, weight and the chemo schedule.
The label’s lower dose for longer-term use. Use right after mixing; don’t use if cloudy.
Not an approved use. Insist on injection-grade product; 2026 FDA and CDC alerts tied supplement-grade batches to serious reactions.
Label: IM injection or slow IV infusion; IM shots can leave the site tender. Wellness clinics also give SC shots. Rotate sites.
No label rule. For chemo protection it’s tied to each cisplatin infusion. For wellness shots there’s no published guidance; take the next one on schedule and don’t double up.
Given 15–30 minutes before chemo to help prevent nerve damage, the label’s approved use in Italy.
LabelTenderness at the site is the label’s usual local effect. Skin rash is very rare and clears after stopping.
LabelInjection-site tenderness (label, IM)
Rotate sites. Spreading redness, swelling or pus needs a doctor.
Skin rash (label: very rare)
Clears after stopping. Stop and tell your prescriber.
Fever, chills, body aches, nausea or dizziness after a dose
Linked in 2026 to endotoxin in supplement-grade glutathione (FDA, CDC). Get prompt care.
Low blood pressure, fainting or shock
Emergency. Seen with contaminated IV, IM and SC products in 2026; at least 3 people were hospitalized (CDC).
IV line problems: vein irritation, clots, leakage
The label lists these as general IV risks. Report pain or swelling at the line.
Get emergency care for trouble breathing, fainting or signs of shock. Get prompt care for fever, chills, severe aches, vomiting, dizziness or a red, swollen site (CDC, 2026).
Usually run on its own.
5 key published human studies, with how many people took part. Animal studies aren’t listed here.
No reduction in nerve damage versus placebo on patient or clinician scales; authors say results do not support this use.
Leal et al., Cancer 2014, PMID 24619793
More patients completed 6 cisplatin cycles with glutathione (58% vs 39%), and quality of life scores improved, including nerve symptoms.
Smyth et al., Ann Oncol 1997, PMID 9261526
Grade 2 to 4 nerve damage after 8 cycles in 2 patients on glutathione vs 11 on placebo (p=0.003); tumor response was not reduced.
Cascinu et al., J Clin Oncol 2002, PMID 12177109
Nerve damage at week 15 in 4 of 24 patients on glutathione vs 16 of 18 on placebo (p=0.0001).
Cascinu et al., J Clin Oncol 1995, PMID 7799029
Well tolerated; no significant difference in Parkinson’s symptom scores versus placebo (p=0.32).
Hauser et al., Mov Disord 2009, PMID 19230029
| Vial | Water | Common dose | Draw | Strength | Action |
|---|---|---|---|---|---|
| 600 mg | 4 mL | 200 mg | 1.33 mL | 150 mg/mL | |
| 1,200 mg | 8 mL | 200 mg | 1.33 mL | 150 mg/mL | |
| 1,500 mg | 10 mL | 200 mg | 1.33 mL | 150 mg/mL |
The Italian label dissolves 600 mg in 4 mL (150 mg/mL) and says to use it within 8 hours. Guides that keep mixed vials for weeks contradict that stability data.
Syringe units for common doses at different water volumes. Select a cell to open it in the calculator.
| Dose | Water added | ||
|---|---|---|---|
| 2 mL | 3 mL | 4 mL | |
| 200 mg | |||
| 250 mg | |||
| 300 mg | |||
| 400 mg | |||
| 500 mg | |||
| 600 mg | |||
U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.
A tripeptide of glutamate, cysteine and glycine. It is the body’s main antioxidant inside cells.
Not approved as a drug in the US. Approved in Italy as TAD injection to help prevent nerve damage from cisplatin-type chemotherapy. Under FDA evaluation (Category 1) for pharmacy compounding (list updated May 14, 2026). In August 2026 FDA told compounders not to use supplement-grade glutathione in injectables.
From the label (TAD, Italy): 600 mg IM or slow IV for ongoing therapy; about 2.5 g IV before each cisplatin dose. From community reports, not established: 200–600 mg IM or SC, 2–3× per week. IV 600–1,200 mg weekly to every 2 weeks. These are the amounts sources reference, not recommendations.
About 14 minutes, according to the prescribing information. Plasma half-life stated in the Italian TAD label: 14.1 ± 9.2 minutes.
Freeze-dried powder with a solvent ampoule: no special storage conditions; 3-year shelf life unopened. Use promptly: the mixed solution is stable for 8 hours at room temperature.
In some cases. Not named on the 2026 list, so the substance is allowed. IV infusions or injections over 100 mL per 12 hours are banned at all times (M2.2) unless given in hospital care, surgery or clinical tests.
Yes. The human studies section lists 5 published studies. The largest, from 2014, included 185 people. No reduction in nerve damage versus placebo on patient or clinician scales; authors say results do not support this use.
For the protocol details
Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.